Download PDF
Aktuelle Dermatologie 2002; 28(5): 153-155
DOI: 10.1055/s-2002-33481
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Selektive Cyclooxygenase-II-Hemmer bei Patienten mit pseudoallergischen Reaktionen auf nichtsteroidale Antiphlogistika

Selective Cyclooxygenase-II-Antagonists for the Treatment of Patients with Intolerance to Non-Steroidal Anti-Inlammatory Drugs (NSAID)C.  Termeer1 , E.  Schöpf1 , J.  C.  Simon1
  • 1Universitäts-Hautklinik, Abteilung für Allergologie und Immundermatologie, Freiburg
Herrn Prof. Dr. E. G. Jung zum 70. Geburtstag gewidmet.
Further Information

Publication History

Publication Date:
22 August 2002 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Pseudoallergische Reaktionen auf nichtsteriodale Antiphlogistika sind mit einer geschätzten Inzidenz von 2 % häufig zu beobachtende Nebenwirkungen bei der Behandlung von chronischen Schmerzzuständen und nicht-infektiösen Entzündungen. Sie können in ihrer schwersten Form anaphylaktoide Schockreaktionen auslösen. Patienten mit diesem Krankheitsbild befinden sich daher häufig in der allergologischen Abklärung. In diesem Artikel werden aktuelle Modelle zur Pathogenese und Möglichkeiten der Diagnostik besprochen. Besonders gehen wir auf die Verwendung neuer Schmerzmittel mit spezifischer Hemmung der Cyclooxigenase II ein, da diese Präparate offenbar eine gute Verträglichkeit bei Patienten mit pseudoallergischen Reaktionen aufweisen.

Abstract

Pseudoallergic reactions to non-steroidal anti-inflammatory drugs (NSAID) are frequently occurring side-effects during the treatment of chronic pain conditions and non-infectious inflammation. The incidence is estimated to be 2 %. In severe cases anaphylactoid reactions may develop. Patients suffering from this disease are therefore frequently transferred to allergologic units for diagnosis. Here, we review current insights into the pathomechanisms and treatment modalities of NSAID-intolerance. Especially, we address the use of new anti-inflammatory drugs with selective inhibition of the Cyclooxigenase II, since these drugs may have a lower risk of pseudo-allergic reactions in patients with NSAID-intolerance.

Literatur

  • 1 Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma.  Thorax. 2000;  55 Suppl. 2 S42-44
    CrossrefPubMedGoogle Scholar
  • 2 Wedi B, Kapp A. Aspirin induced adverse skin reactions: new pathophysiological aspects.  Thorax. 2000;  55 Suppl. 2 S70-71
    PubMedGoogle Scholar
  • 3 Babu K S, Salvi S S. Aspirin and asthma.  Chest. 2000;  118 1470-1476
    CrossrefPubMedGoogle Scholar
  • 4 Capriles-Behrens E, Caplin J, Sanchez-Borges M. NSAID facial angioedema in a selected pediatric atopic population.  J Investig Allergol Clin .Immunol. 2000;  10 277-279
    PubMedGoogle Scholar
  • 5 Wedi B, Kapp A. In-vitro-Diagnostik der Acetylsalicylsäure-Pseudoallergie. In: Garbe C, Rassner G, (Hrsg) Dermatologie - Leitlinien und Qualitätssicherung für Diagnostik und Therapie. Heidelberg; Springer Verlag 1998
    Google Scholar
  • 6 Czech W, Schopf E, Kapp A. Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid.  Inflamm Res. 1995;  44 291-295
    PubMedGoogle Scholar
  • 7 Rieger-Ziegler V, Kranke B, Aberer W. Comparison of Validity of in-vitro testing, skin test and oral provocation in patients with hypersensitivity to acetylsalicylic acid.  Allergologie. 1999;  22 645-649
    PubMedGoogle Scholar
  • 8 Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma.  J Allergy Clin Immunol. 1998;  101 581-586
    PubMedGoogle Scholar
  • 9 Pleskow W W, Stevenson D D, Mathison D A, Simon R A, Schatz M, Zeiger R S. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period.  J Allergy Clin Immunol. 1982;  69 11-19
    PubMedGoogle Scholar
  • 10 Szmidt M, Grzelewska-Rzymowska I, Rozniecki J. Tolerance to aspirin in aspirin-sensitive asthmatics. Methods of inducing the tolerance state and its influence on the course of asthma and rhinosinusitis.  J Investig Allergol Clin Immunol. 1993;  3 156-159
    PubMedGoogle Scholar
  • 11 Corominas M. Mechanisms implicated in adverse reactions to non-steroidal anti-inflammatory drugs.  Clin Exp Allergy. 1998;  28 Suppl. 4 41-45
    PubMedGoogle Scholar
  • 12 Kowalski M L, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, Kornatowski T, Kaliner M A. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients.  Am J Respir Crit Care Med. 2000;  161 391-398
    CrossrefPubMedGoogle Scholar
  • 13 Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, Oates J. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.  Am J Respir Crit Care Med. 1996;  154 1608-1614
    PubMedGoogle Scholar
  • 14 Cowburn A S, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam B K, Penrose J F, Austen F K, Holgate S T, Sampson A P. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.  J Clin Invest. 1998;  101 834-846
    PubMedGoogle Scholar
  • 15 Sanak M, Simon H U, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.  Lancet. 1997;  350 1599-1600
    CrossrefPubMedGoogle Scholar
  • 16 Juergens U R, Christiansen S C, Stevenson D D, Zuraw B L. Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge.  J Allergy Clin Immunol. 1992;  90 636-645
    CrossrefPubMedGoogle Scholar
  • 17 Pauls J D, Simon R A, Daffern P J, Stevenson D D. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics.  Ann Allergy Asthma Immunol. 2000;  85 40-45
    PubMedGoogle Scholar
  • 18 Stevenson D D, Simon R A, Mathison D A, Christiansen S C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics.  Ann Allergy Asthma Immunol. 2000;  85 477-482
    PubMedGoogle Scholar
  • 19 Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma.  Clin Exp Allergy. 2001;  31 219-225
    CrossrefPubMedGoogle Scholar
  • 20 Giercksky K E, Haglund U, Rask-Madsen J. Selective inhibitors of COX-2 - are they safe for the stomach?.  Scand J Gastroenterol. 2000;  35 1121-1124
    CrossrefPubMedGoogle Scholar
  • 21 Marks F, Harrell K, Fischer R. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.  South Med J. 2001;  94 256-257
    PubMedGoogle Scholar
  • 22 Zollner T M, Ahlbach S, Kaufmann R, Boehncke W H. Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents.  Dtsch Med Wochenschr. 2001;  26 386-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Stevenson D D, Simon R A. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.  J Allergy Clin Immunol. 2001;  108 47-51
    CrossrefPubMedGoogle Scholar
  • 24 Sanchez B M, Capriles-Hulett A, Caballero-Fonseca F, Perez C R. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.  Ann Allergy Asthma Immunol. 2001;  87 201-204
    PubMedGoogle Scholar

Dr. C. Termeer

Universitäts-Hautklinik · Abteilung für Allergologie und Immundermatologie ·

Hauptstraße 7 · 79104 Freiburg